Search for: "In re Lantus Direct Purchaser Antitrust Litigation" Results 1 - 5 of 5
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
Sanofi Decision Presents Opportunities to Clear the Patent Thicket for Generic Pharmaceuticals
25 Mar 2020, 4:15 am by Joel Wallace
In re Lantus Direct Purchaser Antitrust Litigation (Feb. 2020). [read post]
IPWatchdog - http://www.ipwatchdog.com/
Sanofi Decision Presents Opportunities to Clear the Patent Thicket for Generic Pharmaceuticals
25 Mar 2020, 4:15 am by Joel Wallace
In re Lantus Direct Purchaser Antitrust Litigation (Feb. 2020). [read post]
IPWatchdog.com | Patent Copyright Trademark - http://www.ipwatchdog.com
Improper Listing of Insulin-Pen Patents in the Orange Book
27 Feb 2020, 10:25 am by Dennis Crouch
In re Lantus Direct Purchaser Antitrust Litig., 18-2086, 2020 WL 728628 (1st Cir. [read post]
Patently-O - http://patentlyo.com/patent
FTC Continues to Rage Against Device Patent Listings in the Orange Book
26 Mar 2024, 7:01 pm by Kurt R. Karst
  FTC compares Teva’s listed patents to those at issue in the 2020 First Circuit decision in In re Lantus Direct purchaser Antitrust Litigation, where the Court held that device component patents that do not explicitly claim the drug product cannot be listed in the Orange Book. [read post]
FDA Law Blog - https://www.thefdalawblog.com/
FTC’s Campaign Against Improper Orange Book Listings Continues with Amicus Brief in Teva’s Challenge of Amneal Asthma Inhaler ANDA
3 Apr 2024, 1:07 pm by Bevin Newman
The FTC cites favorably the First and Second Circuit opinions in In re Lantus Direct Purchaser Litigation, 950 F.3d 1 (2020) and United Food & Com. [read post]
Antitrust Law Blog - http://www.antitrustlawblog.com/